EMJ Podcast: Insights For Healthcare Professionals

In the final episode of this series on colorectal cancer screening, Matt Rutter explores the future of early diagnosis and prevention. From AI in endoscopy and personalised screening pathways to emerging technologies and unanswered research questions, this episode looks at how innovation could transform bowel cancer detection and prevention over the next decade. Timestamps: 58:09 – Innovations in colorectal cancer detection 05:10 – Personalised screening pathways 06:15 – Unanswered questions in colorectal cancer screening research 07:25 – One major change for healthcare systems to improve screening outcomes 07:57 – Colorectal cancer screening in 10–15 years 9:05 – The next 5 years in bowel screening, FIT testing, and colonoscopy practice

How do faecal immunochemical tests and colonoscopy work together to improve colorectal cancer detection? In Part 2, Matt Rutter discusses the importance of quality in endoscopy, including colonoscopy performance indicators, interval cancers, variation in outcomes, and the role of large-scale data in improving screening pathways. This episode highlights why quality improvement remains central to preventing colorectal cancer. Timestamps 01:08 – Endoscopy quality 03:18 – Colonoscopy quality indicators 04:56 – Variations between colonoscopy providers 08:05 – The National Endoscopy Database 10:16 – Interval cancers 13:53 – Interpreting FIT Results

This episode has been funded by AstraZeneca and is intended for healthcare professionals. All content has been developed independently by AMJ, and AstraZeneca has had no influence over the content of this podcast. The views expressed are those of the participating experts and do not necessarily reflect the views of AMJ or AstraZeneca. This material is intended for educational and scientific exchange purposes only. Thoracic medical oncologist Julia Rotow and neuro-oncologist David O. Kamson discuss how they manage central nervous system metastases in EGFR-mutated advanced non-small cell lung cancer. They begin with brain metastases found at diagnosis, and how the current frontline regimens have changed the decision between systemic therapy with MRI surveillance, upfront stereotactic radiosurgery, and, for some patients, both. They also explain where whole brain radiotherapy now sits in their own practice. The speakers then discuss leptomeningeal disease: why it is often recognized late, what they add to the standard workup, and the symptoms that make them worry about hydrocephalus and cauda equina involvement. They review systemic and local options after progression on a third-generation tyrosine kinase inhibitor, and close with where they each see the biggest gap in current central nervous system management. Speakers David O. Kamson, Johns Hopkins University, Baltimore, Maryland, USA Julia Rotow, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Professor Matt Rutter joins host Catherine Glass to explore the evolution of colorectal cancer screening, from the development of national bowel cancer screening programmes to the growing role of faecal immunochemical tests, colonoscopy, and polyp management. Drawing on lessons from more than two decades of screening, this episode examines how screening pathways have changed, how our approach to colorectal polyps has evolved, and how risk stratification could shape the future of colorectal cancer prevention. Timestamps: 01:10 – Evolution of colorectal cancer screening 05:32 – FIT and colonoscopy 7:27 – Managing polyps 10:06 – Risk-based screening  

In this rapid-fire episode, Matt Rutter answers key questions about colorectal cancer screening, from the importance of early detection and the role of faecal immunochemical tests to misconceptions about screening, colonoscopy quality, and the future of bowel cancer prevention. Perfect for listeners looking for concise insights into how screening is improving outcomes in colorectal cancer.

In the final episode, Linda Wesp explores the future of LGBTQIA+ healthcare. From clinician education and nursing leadership to healthcare policy and patient partnership, discover the changes needed to build more equitable and inclusive health systems. Timestamps: 01:06 – Gaps in clinician training 04:04 - Practical changes 06:11 – The role of nursing in LGBTQIA+ health equity 08:04 – Community involvement in designing healthcare services 09:43 – Legislation changes 11:45 – The future of LGBTQIA+ healthcare

How has HIV care evolved over the past 2 decades? Linda Wesp reflects on lessons from the HIV epidemic, the importance of community partnership, reducing stigma in healthcare, and delivering person-centred care for people living with HIV. Timestamps: 01:03 – The evolution of HIV care 06:23 – Lessons from the AIDS crisis 08:54 - The Wisconsin HIV/AIDS Oral History Project 10:31 – Reducing stigma in healthcare 14:06 – Holistic, patient-centred care 16:22 – Community voices

This content was funded by Johnson & Johnson. This material is intended for educational and scientific exchange purposes only. It is not intended to be promotional and should not be used to make treatment decisions for any individual patient. The views expressed are those of the speaker and do not necessarily reflect those of Johnson & Johnson.   Atypical EGFR mutations make up approximately 5 to 10% of EGFR-mutant NSCLC, and because some assays only report exon 19 deletions and L858R, they are easy to miss. In this short podcast, Melina Marmarelis, thoracic oncologist at the University of Pennsylvania, explains why these mutations often respond differently to EGFR TKIs and how to pick them up on NGS. She also walks through CHRYSALIS-2 Cohort C, which evaluated amivantamab plus lazertinib in treatment-naive and previously treated patients.   Explore: •    Why G719X and other atypical mutations alter the ATP-binding pocket differently from exon 19 del and L858R •    Which assays can miss atypical mutations, and when broader NGS is needed •    What CHRYSALIS-2 Cohort C evaluated, and the limitations of a single-arm phase 1/1b study •    How the ASCO living guideline now addresses atypical EGFR alterations   Amivantamab plus lazertinib is not approved by the US Food and Drug Administration for the treatment of atypical EGFR-mutated non-small cell lung cancer. This content includes discussion of investigational and unapproved uses. The data presented do not establish safety or efficacy for any unapproved use. Prescribers should consult the full Prescribing Information for approved indications and complete safety information.    Speaker: Melina E. Marmarelis, Associate Professor of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

In this quickfire episode, Linda Wesp answers rapid-fire questions on gender-affirming care, HIV, culturally safe healthcare, and LGBTQIA+ health. Discover practical insights on tackling stigma, improving clinician education, and creating more inclusive healthcare environments in just a few minutes.

Linda Wesp joins host Catherine Glass to discuss how clinicians can deliver culturally safe, gender-affirming healthcare across all areas of practice. From informed consent models and trauma-informed care to supporting patients who are transgender and gender-diverse, this episode explores practical approaches to improving healthcare experiences and outcomes. Timestamps: 01:03 – The historical timeline of gender-affirming care 04:49 – Gender-affirming care outside of specialist clinics 07:06 - Breaking down misconceptions of gender-affirming care 09:25 – Informed consent models 13:30 – Culturally safe care 17:59 – Listening to transgender youth 20:36 – Creating trauma informed environments

In the final episode, Tonia Poteat discusses how healthcare systems can move beyond recognising health inequities to implement meaningful change. From community-engaged research and inclusive policy development to the future priorities for transgender health research, this episode explores practical strategies for advancing equitable healthcare.  Timestamps:  01:00 – Translating Evidence Into Practice  05:30 – Policy Change and Challenging Healthcare Systems

Why do transgender communities continue to experience profound health inequities? In Part 2, Tonia Poteat examines the structural and social determinants influencing transgender health, the persistent disparities in HIV prevention and care, and the importance of addressing housing, employment, stigma, and gender affirmation alongside traditional healthcare interventions.  Timestamps:  01:01 – Political Determinants of Health  04:00 – Gender and Racial Minorities – HIV  06:04 – Why Intersectionality is Important in HIV Care  08:52 – Responding to Non-Healthcare Challenges

Sagar Lonial discusses advances in multiple myeloma treatment, the evolving role of immunotherapy and minimal residual disease, unmet needs in relapsed disease, lessons from research, and emerging technologies shaping future care.  Timestamps:  00:00 – Introduction 01:24 – Inspiration for Myeloma Research 03:20 – Transformative Myeloma Treatment Developments 05:03 – Translating Science into Treatment 07:41 – Future of Immunotherapy in Myeloma 09:45 – Unmet Needs After Relapse 10:53 – Lessons from Research Setbacks 13:05 – Future Role of MRD Assessment 15:50 – Fostering Research Innovation 17:50 – Emerging Advances in Myeloma 19:45 – Three Wishes for Myeloma 

Tonia Poteat joins host Catherine Glass to explore how intersectionality provides a more complete understanding of health inequities. Together, they discuss why single-axis approaches often fail, how overlapping identities shape health outcomes, and how clinicians can begin applying intersectional thinking to improve patient care and healthcare research.   Timestamps: 01:00 – Intersectionality 02:26 – Why Intersectionality is Important in HIV Care 04:13 – Intersectionality and Gender-Diverse People

In this rapid-fire episode, Tonia Poteat answers key questions on intersectionality, transgender health, and health equity. Discover what drives her work in LGBTQIA+ health, common misconceptions surrounding transgender healthcare, the biggest challenges facing transgender communities today, and the practical steps healthcare organisations can take to become more inclusive in just a few minutes.

In the final episode of this series, Dr Carl Streed Jr explores the evolving evidence base, risk assessment, and policy landscape in transgender healthcare. From cardiovascular outcomes and research challenges to the interpretation of emerging evidence in healthcare and sport, this episode examines how clinicians, researchers, and policymakers can translate evidence into guidance while advancing inclusive, equitable care. Timestamps: 01:00 – Cardiovascular Risk in Transgender Patients 04:29 – Sports Governing Bodies 06:05 – Methodological Challenges 07:26 – Translating Evidence into Guidance

How can clinical practice evolve to deliver more inclusive gender-affirming care? In Part 2, Carl Streed Jr shares insights from his research on implementing equitable healthcare, including the impact of targeted education, barriers to care delivery, and the role of training programmes in building long-term clinical competence. A must-listen for clinicians seeking to understand the evidence, practice, and future of transgender healthcare. Timestamps: 01:08 – Providing Training on Gender Affirming Care 02:32 – Barriers to Gender Affirming Care 03:29 – Well-Rounded Gender-Affirming Care 04:45 – When to Look at Sex, and When to Look at Affirmed Gender? 06:27 – Focusing on the Person and the Medicine 08:11 – Continuity of Care 10:20 – Advocacy

Carl Streed Jr joins host Catherine Glass to explore how healthcare systems can advance equity and inclusion for sexual and gender minority populations. From improving continuity of care and electronic health record design to addressing structural disparities and embedding equity at a systems level, this episode examines how research and implementation can transform LGBTQIA+ healthcare. Timestamps: 01:02 – Continuity of Care 02:06 – Reshaping Electronic Health Records 04:08 – Equity at a Systems Level

In this rapid-fire episode, Carl Streed Jr answers key questions about transgender healthcare and LGBTQIA+ health equity, from the biggest barriers and research priorities to clinical training, inclusive practice, and the future of gender-affirming care. Perfect for listeners looking for concise insights into the challenges and opportunities shaping equitable healthcare.

This episode was funded by Stemline Therapeutics, Inc., a Menarini Company Group, and is intended for United States healthcare professionals only. The opinions expressed here are solely those of the named speaker and do not represent those of his affiliated institution. His participation in this discussion does not constitute, and should not be construed as, endorsement, recommendation, or promotion of any product, service, or organization. In this podcast, we shine a light on blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and highly aggressive hematologic malignancy. Before 2018, there were no approved treatments for BPDCN, and oncologists typically used chemotherapy regimens commonly used for acute leukemias and lymphomas that were associated with limited durability and high rates of induction mortality. The landscape changed when the FDA approved tagraxofusp, a CD123-directed fusion protein, as the first therapy approved for adult and pediatric patients 2 years and older with BPDCN. Listen to Thomas LeBlanc explore the safety and efficacy of tagraxofusp from STML-401-0114 and real-world evidence, as well as how he approaches optimizing clinical management and interdisciplinary care. Topics covered: How BPDCN presents and what steps are needed to make a correct diagnosis The safety and efficacy outcomes from STML-401-0114, including patient subgroups based on patients' age, fitness, or baseline skin burden How real-world evidence complements the findings from the pivotal STML-401-0114 study How the 'Prepare, Look, Apply, and Next Steps' (PLAN) management framework can help your team monitor and manage adverse events Speaker: Thomas LeBlanc Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, North Carolina, USA   INDICATION Tagraoxfusp is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older   IMPORTANT SAFETY INFORMATION Boxed WARNING: CAPILLARY LEAK SYNDROME Capillary Leak Syndrome (CLS), which may be life-threatening or fatal, can occur in patients receiving tagraxofusp. Monitor for signs and symptoms of CLS and take actions as recommended.   WARNINGS AND PRECAUTIONS  Capillary Leak Syndrome Capillary leak syndrome (CLS), including life-threatening and fatal cases, has been reported among patients treated with tagraxofusp. In patients receiving tagraxofusp in clinical trials, the overall incidence of CLS was 53% (65/122), including Grade 1 or 2 in 43% (52/122) of patients, Grade 3 in 7% (8/122) of patients, Grade 4 in 1% (1/122) of patients, and four fatalities (3%). The median time to onset was 4 days (range-1 to 46 days), and all but 5 patients experienced an event in Cycle 1. Before initiating therapy with tagraxofusp, ensure that the patient has adequate cardiac function and serum albumin is greater than or equal to 3.2 g/dL. During treatment with tagraxofusp, monitor serum albumin levels prior to the initiation of each dose of tagraxofusp and as indicated clinically thereafter, and assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema, including pulmonary edema, hypotension or hemodynamic instability. Hypersensitivity Reactions Tagraxofusp can cause severe hypersensitivity reactions. In patients receiving tagraxofusp in clinical trials, hypersensitivity reactions were reported in 43% (53/122) of patients treated with tagraxofusp and were Grade ≥ 3 in 7% (9/122). Manifestations of hypersensitivity reported in ≥ 5% of patients include rash, pruritus, and stomatitis. Monitor patients for hypersensitivity reactions during treatment with tagraxofusp. Interrupt tagraxofusp infusion and provide supportive care as needed if a hypersensitivity reaction should occur. Hepatotoxicity Treatment with tagraxofusp was associated with elevations in liver enzymes. In patients receiving tagraxofusp in clinical trials, elevations in ALT occurred in 79% (96/122) and elevations in AST occurred in 76% (93/122). Grade 3 ALT elevations were reported in 26% (32/122) of patients. Grade 3 AST elevations were reported in 30% (36/122) and Grade 4 AST elevations were reported in 3% (4/122) of patients. Elevated liver enzymes occurred in the majority of patients in Cycle 1 and were reversible following dose interruption. Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with tagraxofusp. Withhold tagraxofusp temporarily if the transaminases rise to greater than 5 times the upper limit of normal and resume treatment upon normalization or when resolved. ADVERSE REACTIONS: Most common adverse reactions (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, pyrexia, peripheral edema, and weight increase. Most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST. Please see Full Prescribing Information, including Boxed WARNING. To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. MED-05440 / © 2026 Stemline Therapeutics, Inc. All rights reserved. 07/2026

In the final episode of this series, Angela Frazer-Wicks MBE reflects on her journey from trauma and loss to advocacy and system change. She discusses the value of peer support, the importance of incorporating lived experience into service design, and the progress made in understanding maternal vulnerability. This episode offers practical insights into building more compassionate, preventative, and trauma-informed systems for women and families. Timestamps: 00:00–00:42: Intro 00:43–05:06: New beginnings 05:07–09:49: Lived experiences 09:50–14:49: Peer support 14:50–19:49: Care reforms 19:50–20:16: Outro 

What are the health impacts of child removal and family separation? In Part 2 of this series, Angela Frazer-Wicks MBE discusses the often overlooked psychological and emotional consequences of child removal and family separation. She shares insights into grief, stigma, shame, and the long-term impact these experiences can have on maternal wellbeing. This episode explores gaps in support services and highlights the crucial role healthcare professionals can play in helping mothers navigate loss and recovery. Timestamps: 00:00–00:44: Intro 00:45–06:42: Unresolved grief 06:43–09:54: Overcoming shame 09:55–11:19: Mental support 11:20–13:56: HCP advocacy 13:57–17:07: Building trust 17:08–17:26: Outro

In this episode of Onc Now, Miguel Reis Ferreira explores the evolving relationship between the microbiome and cancer, from treatment-related toxicity and tumour-associated bacteria to the potential of AI and microbiome-based biomarkers in precision oncology. Timestamps:   00:00 – Introduction   01:28 – Clinical and Research Interests  06:52 – Microbiome and Treatment Toxicity  10:12 – Personalising Radiotherapy with Biomarkers  12:40 – Bacteria Within Tumours  18:02 – The Future of Oncomicrobiology  19:17 – AI in Radiation Oncology  21:48 – Unanswered Questions in Microbiome Research  23:35 – Three Wishes for Oncology 

Angela Frazer-Wicks MBE joins host Saranya Ravindran to explore the complex relationship between trauma, domestic abuse, maternal mental health, and safeguarding. Drawing on her lived experience, Angela discusses the impact of coercive control, barriers to accessing support, and opportunities for earlier intervention by healthcare professionals. This episode examines how clinicians can better recognise vulnerability and provide trauma-informed care before families reach crisis point. Timestamps: 00:00–00:47: Intro 00:47–04:08: Angela's story 04:09–06:10: Childhood trauma 06:11–09:34: Systemic failures 09:34–12:55: Coercive control 12:55–13:14: Outro

In this rapid-fire episode, Angela Frazer-Wicks MBE shares powerful insights from her lived experience of maternal mental health challenges, domestic abuse, and family separation. From common misconceptions about vulnerable mothers to the support every woman in crisis should have access to, this concise episode offers valuable perspectives for healthcare professionals seeking to better understand and support women facing adversity. Perfect for listeners short on time but looking to gain meaningful insights in just a few minutes.

In the final episode of this series, Professor Habib Naqvi MBE looks ahead to the future of equitable healthcare. From the economic impact of health inequalities and rebuilding trust with underserved communities to the role of patients in shaping healthcare policy, he explores the changes needed to create a fairer NHS. The episode also examines emerging challenges in health equity, lessons from international approaches, and the reasons for optimism about the future of race equity and healthcare. Timestamps: ·       1:07 – Equity: A Moral and Economic Priority ·       04:06 – The Bigger Picture ·       05:28 – Building Trust ·       07:50 – International Partnerships ·       10:00 – New Trends ·       11:48 – Patients and Communities ·       14:30 – Intersectionality ·       15:59 – Looking Forward ·       17:46 - Optimism

What roles do leadership, workforce equality, and accountability play in achieving health equity? In Part 2, Professor Habib Naqvi MBE explores the link between staff experience and patient outcomes, discusses the realities faced by ethnic minority NHS staff, examines why translating good intentions into meaningful action remains challenging, and explains how data, leadership, and openly addressing racism are essential to driving lasting change across the healthcare system. Timestamps ·       01:01– Workforce Inequality ·       05:37 – From Policy to Action ·       07:29 – Data Limitations ·       09:53 – The 'Model Organisation' ·       12:34 – Accountability

In this episode of Hema Now, Lucas Kühne explores the evolving landscape of immune thrombotic thrombocytopenic purpura, discussing advances in treatment, the importance of early recognition and accurate diagnosis, the growing role of real-world evidence, and why international collaboration is critical to accelerating research and improving patient care in rare thrombotic microangiopathies. Timestamps:   00:00 – Introduction  01:40 - Career inspiration and TMA interest   03:11 - Major advances in iTTP treatment   05:05 - Recognising iTTP earlier   07:08 - Distinguishing between TMAs   09:05 - Value of real-world evidence   12:13 - Future priorities in iTTP research   13:32 - Importance of research collaboration   14:57 - Advice for future researchers   15:53 - Future of TMA care 

In this episode, Habib Naqvi explores the current state of race and health inequalities in the UK. Marking the fifth anniversary of the NHS Race and Health Observatory, he reflects on how the conversation around health equity has evolved, discusses the persistent disparities affecting ethnic minority communities, examines the role of healthcare systems and wider social determinants, and addresses the misconceptions that continue to hinder progress towards equitable healthcare.

 In this rapid-fire episode, Habib Naqvi answers key questions on health equity, race and the future of the NHS. From the most overlooked determinants of health and common misconceptions about health inequalities to leadership, the achievements of the NHS Race and Health Observatory, and the changes needed to create a fairer healthcare system, this episode offers concise insights for anyone interested in improving health outcomes and advancing equity.

This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits. The speakers were compensated by Sanofi and Regeneron in connection with this program.   COPD trial outcomes are not all equal, yet conventional endpoints can make it difficult to weigh severe events, exacerbations, lung function, and symptom burden within a single clinical picture.   In this AMJ podcast, Sanjay Ramakrishnan and Simon Couillard discuss how win ratio methodology may help capture a broader, more clinically meaningful view of treatment benefit by comparing outcomes across a prespecified hierarchy.   Listen to the full episode to learn:   Why standard COPD endpoints may not tell the full story How win ratio analysis prioritizes outcomes by clinical importance What the pooled BOREAS and NOTUS analysis showed How this approach could shape future respiratory trial design Speakers: Sanjay Ramakrishnan, Clinical Senior Lecturer, UWA Medical School, Centre for Respiratory Health, The University of Western Australia, Perth, Australia Simon Couillard, Professor, Faculty of Medicine and Health, Université de Sherbrooke, Quebec, Canada

In the final episode, Veeru Kasivisvanathan discusses the future of prostate cancer diagnosis, including AI-assisted MRI interpretation, genomic risk prediction, polygenic risk scores, and the opportunities and challenges of population screening. Discover how precision technologies could reshape prostate cancer care over the next decade. Timestamps: 00:57 – AI and MRI 02:25 – PARADIGM study 02:51 – Large-scale MRI screening 04:56 – Genomics and polygenic risk scores 06:45 – Future optimism of prostate cancer

Veeru Kasivisvanathan joins host Catherine Glass to discuss how MRI-first pathways have transformed prostate cancer diagnosis. Discover how the landmark PRECISION trial reshaped clinical practice, why targeted biopsy improves diagnostic accuracy, and how clinicians are balancing precision with access as MRI becomes the new standard. Timestamps: 01:05 – Traditional diagnostic approaches 02:55 – PRECISION trial 05:03 – MRI challenges

Veeru Kasivisvanathan joins host Catherine Glass to discuss how MRI-first pathways have transformed prostate cancer diagnosis. Discover how the landmark PRECISION trial reshaped clinical practice, why targeted biopsy improves diagnostic accuracy, and how clinicians are balancing precision with access as MRI becomes the new standard. 01:05 – Traditional diagnostic approaches 02:55 – PRECISION trial 05:03 – MRI challenges

In this rapid-fire episode, Veeru Kasivisvanathan answers key questions on prostate cancer diagnosis, MRI, prostate biopsy, overdiagnosis, AI, and future innovations. From common misconceptions to emerging technologies, this concise episode delivers expert insights into one of the fastest-evolving areas of urology.

 In this episode, Anna Caldwell speaks with paediatric allergist and immunologist Zachary Rubin about the rise of medical misinformation, vaccine hesitancy, and the opportunities and challenges of social media in healthcare. They discuss common allergy myths, how clinicians can effectively communicate evidence-based medicine online, and what patients can do to prepare for the 2026 allergy season.

In this episode of Hema Now, Megan Melody speaks about the evolution of CAR-T cell therapy and its impact on lymphoma care. She explores the major advances that have transformed outcomes for patients with relapsed and refractory disease, the unanswered questions shaping current research, and the practical challenges of building successful cellular therapy programmes. The conversation also covers equitable access to treatment, the role of quality standards and accreditation, personalised approaches to CAR-T therapy, and the importance of physician leadership and mentorship in shaping the future of academic haematology. Timestamps:   00:00 – Introduction   01:13 – Journey into Haematology and Lymphoma   04:19 – Major Advances in CAR-T   06:00 – Unanswered Questions After CAR-T   07:45 – Building Successful Cellular Therapy Programmes   09:06 – Improving Access to CAR-T   12:55 – Evolving Standards in Cellular Therapy   14:16 – Towards Personalised CAR-T Treatment   16:00 – Physician Leadership in Academic Medicine   17:10 – Career Advice for Future Specialists   19:02 – Future Directions in Cellular Therapy 

What does the future hold for kidney stone management? In Part 3, David S. Goldfarb explores disparities in care, promising areas of research, and the move towards more personalised approaches to prevention and treatment. He also discusses the impact of climate change on kidney stone risk and shares why he remains optimistic about the future of kidney stone care. Timestamps: 00:46 – Global warming 02:23 – Emerging research/treatments 03:57 – Asymptomatic kidney stones 04:58 – Broad, empiric approach to treatment 08:29 – Occupation as a risk factor for kidney stones 09:56 – Multidisciplinary care 11:51 – Climate change 13:47 – Calcium and kidney stones

What are the most effective ways to prevent kidney stones from recurring? In Part 2, David S. Goldfarb discusses evidence-based prevention strategies, including dietary counselling, hydration, and the role of pharmacological therapies.

In this episode of Onc Now, Vernon Sondak reflects on the remarkable evolution of melanoma care over the course of his career. He discusses how breakthroughs in surgery, immunotherapy, targeted therapies, and neoadjuvant treatment have transformed outcomes for patients with melanoma and influenced treatment strategies across oncology. The conversation also explores the challenges of paediatric melanoma, the importance of multidisciplinary collaboration, and the future priorities for melanoma research and patient care.  Timestamps:   00:00 – Introduction   01:30 - Melanoma Care Through the Years   06:52 - Sentinel Node Biopsy Impact Today   12:28 - Paediatric Melanoma Care Challenges   21:45 - Collaboration Driving Melanoma Progress   24:57 - Translating Research into Patient Care   31:30 - Exciting Advances in Systemic and Neoadjuvant Therapy   39:06 - Three Wishes for Melanoma Care 

What causes kidney stones to form, and why are they becoming increasingly common? In Part 1, David S. Goldfarb explores the physiological mechanisms behind kidney stone disease, the evolving roles of diet, metabolism, and hydration, and the links between kidney stones and broader metabolic conditions, including metabolic syndrome and fatty liver disease. He also reflects on how advances in research have transformed our understanding of risk factors, genetics, and disease prevention.

In this quickfire episode, David S. Goldfarb answers key questions about kidney stone disease, from common misconceptions and risk factors to the roles of genetics, lifestyle, hydration, and prevention. He also discusses changing prevalence trends, and the steps clinicians and patients can take to reduce the burden of this increasingly common condition.

In the final episode, Salvatore Brugaletta explores the future of percutaneous coronary intervention, including AI-assisted decision-making, personalised device selection, and next-generation coronary therapies. Discover how innovation could further improve outcomes for patients with coronary artery disease.  Timestamps:  0:50 – 10 years from now  2:17 – AI  3:47 – Personalised medicine  5:34 – Breakthroughs   7:02 – Salvatore's vision

In Part 2, Salvatore Brugaletta discusses the rise, challenges, and future potential of bioresorbable vascular scaffolds. Learn how advances in material science are improving device performance, which patients may benefit most, and what emerging technologies could redefine coronary intervention.  Timestamps:  0:52 – Bioresorbable scaffold enthusiasm  3:16 – Which patients will benefit?  4:40 – Material Science Advancements  5:48 – Device Innovations  7:02 – Translational Hurdles 

In this episode of Hema Now, Jorge Cortes reflects on the remarkable evolution of leukaemia treatment throughout his career, from the transformation of chronic myeloid leukaemia outcomes through targeted therapies to the rapidly changing landscape of acute myeloid leukaemia. He discusses the growing importance of biomarkers and patient-reported outcomes, the value of international collaboration, and how precision medicine is reshaping clinical research. Looking ahead, Cortes shares the developments in immunotherapy and personalised care that he believes could define the next era of leukaemia treatment. Timestamps:   00:00 – Introduction   01:01 – Inspiration for Haematology and Leukaemia  02:40 – Transforming Chronic Myeloid Leukaemia Care  04:55 – Future Challenges in CML  07:21 – Evolution of AML Treatment  09:50 – Biomarkers and Personalised Leukaemia Care  11:45 – Balancing Outcomes and Quality of Life  14:02 – International Collaboration in CML  16:33 – The Future of Clinical Research  20:03 – Building a Haematology Academic Career  22:04 – Exciting Advances in Leukaemia Research

Salvatore Brugaletta joins host Catherine Glass to explore how intracoronary imaging has transformed modern percutaneous coronary intervention (PCI). From intravascular ultrasound and optical CT to stent optimisation, vascular dysfunction, and AI-enhanced image interpretation, this episode examines the technologies improving procedural precision and patient outcomes.  Timestamps:  0:55 – IVUS and OCT  2:58 – Endothelial recovery  4:55 – Stent failure mechanisms  6:19 – Barriers to adoption  8:18 – Innovations in imaging 

In this rapid-fire episode, Salvatore Brugaletta answers key questions on interventional cardiology, coronary imaging, bioresorbable scaffolds, vascular healing, and the future of percutaneous coronary intervention. From AI-assisted procedures to device innovation and career advice, this concise episode offers expert insight into the evolving world of coronary intervention.   

In this episode of Onc Now, Mary Disis, Director of the University of Washington's Medicine Cancer Vaccine Institute, Seattle, USA, explores the science and future of cancer vaccines. She discusses how vaccines fit into today's immunotherapy landscape, the evolution of human epidermal growth factor receptor 2 (HER2)-targeted therapies, progress in breast cancer vaccines, the promise of cancer prevention, and the key priorities for survivorship and future oncology care.  Timestamps:   00:00 – Introduction   01:28 – Cancer Vaccines Explained   03:57 – Journey Into Cancer Immunology   06:38 – Cancer Vaccines in Immunotherapy   10:02 – Leading the Cancer Vaccine Institute   13:26 – Progress in Breast Cancer Vaccines   18:39 – HER2 Research and Treatment Evolution   21:30 – Future of Preventive Cancer Vaccines   26:39 – Priorities for Cancer Survivorship   30:30 – Three Wishes for Oncology's Future 

How does scientific evidence become public policy? In the final episode, Christopher Cogle discusses the challenges of translating healthcare innovation into large-scale policy change. Topics include housing policy and mortality, youth tobacco use, vaping regulation, and how the COVID-19 pandemic reshaped public health decision-making.  Timestamps:  00:49 – Public Startup  07:08 - Challenges  15:01 – Housing policy  16:28 – Tobacco policy  19:05 – COVID-19

In Part 2, Christopher Cogle examines the long-term realities facing cancer survivors. From vaccine hesitancy and quality-of-life disparities to healthcare access and survivorship policy, this episode explores how systems can better support patients beyond active treatment.  Timestamps:  00:50 – Vaccine hesitancy  04:33 – QoL after cancer  07:30 – Policy support   11:10 – Survivorship care